These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 31356230)

  • 21. Pembrolizumab as first-line therapy in programmed death ligand 1-positive advanced lung cancer: Is it as effective as we think it is?
    Goldstein DA; Bilal U; Prasad V
    Cancer; 2017 Oct; 123(20):3872-3874. PubMed ID: 28662268
    [No Abstract]   [Full Text] [Related]  

  • 22. Susac's syndrome as an immune-related adverse event after pembrolizumab: a case report.
    De Groot M; Compter A; De Langen AJ; Brandsma D
    J Neurol; 2020 Jan; 267(1):282-284. PubMed ID: 31701330
    [No Abstract]   [Full Text] [Related]  

  • 23. Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer.
    Imai H; Wasamoto S; Yamaguchi O; Suzuki K; Sugiyama T; Uchino J; Minemura H; Osaki T; Ishii H; Umeda Y; Mori K; Kotake M; Kagamu H; Morozumi N; Taniguchi H; Kasai T; Minato K; Kaira K
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):457-466. PubMed ID: 31853661
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Response to the Letter to the Editor: Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLC.
    Higashiyama RI; Yoshida T
    J Thorac Oncol; 2024 Sep; 19(9):e33-e34. PubMed ID: 39242142
    [No Abstract]   [Full Text] [Related]  

  • 25. Diabetic ketoacidosis following immunotherapy for lung cancer.
    Skorpen PK; Margull J
    Tidsskr Nor Laegeforen; 2019 Feb; 139(4):. PubMed ID: 30808100
    [No Abstract]   [Full Text] [Related]  

  • 26. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.
    Naqash AR; Appah E; Yang LV; Muzaffar M; Marie MA; Mccallen JD; Macherla S; Liles D; Walker PR
    J Immunother Cancer; 2019 Jul; 7(1):169. PubMed ID: 31277704
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Q-TWiST Analysis to Assess Benefit-Risk of Pembrolizumab in Patients with PD-L1-Positive Advanced or Metastatic Non-small Cell Lung Cancer.
    Huang M; Pietanza MC; Samkari A; Pellissier J; Burke T; Chandwani S; Kong F; Pickard AS
    Pharmacoeconomics; 2019 Jan; 37(1):105-116. PubMed ID: 30515719
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prurigo nodularis and pembrolizumab: A therapeutic challenge.
    Fattore D; Panariello L; Annunziata MC; Fabbrocini G
    Eur J Cancer; 2019 Mar; 110():8-10. PubMed ID: 30735833
    [No Abstract]   [Full Text] [Related]  

  • 29. Cemiplimab: a new option for the treatment of non-small-cell lung cancer.
    Khalife N; Kordahi M; Felefly T; Saleh K
    Future Oncol; 2021 Jul; 17(20):2559-2562. PubMed ID: 34047193
    [No Abstract]   [Full Text] [Related]  

  • 30. Intravenous immunoglobulin efficacy on pembrolizumab induced severe toxic epidermal necrolysis.
    Kian W; Zemel M; Elobra F; Sharb AA; Levitas D; Assabag Y; Alguayn F; Yakobson A; Rouvinov K; Fuchs L
    Anticancer Drugs; 2022 Jan; 33(1):e738-e740. PubMed ID: 34321417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cascade of immunologic adverse events related to pembrolizumab treatment.
    Dhenin A; Samartzi V; Lejeune S; Seront E
    BMJ Case Rep; 2019 Jun; 12(6):. PubMed ID: 31167767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Life threatening pembrolizumabinduced myositis in a patient treated for advanced adenocarcinoma of the lung.
    Robinson SD; Lai C; Hotton G; Anand G
    Acute Med; 2019; 18(3):197-199. PubMed ID: 31536059
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
    Gandhi L; Rodríguez-Abreu D; Gadgeel S; Esteban E; Felip E; De Angelis F; Domine M; Clingan P; Hochmair MJ; Powell SF; Cheng SY; Bischoff HG; Peled N; Grossi F; Jennens RR; Reck M; Hui R; Garon EB; Boyer M; Rubio-Viqueira B; Novello S; Kurata T; Gray JE; Vida J; Wei Z; Yang J; Raftopoulos H; Pietanza MC; Garassino MC;
    N Engl J Med; 2018 May; 378(22):2078-2092. PubMed ID: 29658856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
    Fujita K; Uchida N; Kanai O; Okamura M; Nakatani K; Mio T
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1105-1109. PubMed ID: 29675747
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progression of Hypopituitarism and Hypothyroidism after Treatment with Pembrolizumab in a Patient with Adrenal Metastasis from Non-small-cell Lung Cancer.
    Yamagata S; Kageyama K; Takayasu S; Asari Y; Makita K; Terui K; Daimon M
    Intern Med; 2019 Dec; 58(24):3557-3562. PubMed ID: 31462588
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute Tubulointerstitial Nephritis: A Case Report on Rare Adverse Effect of Pembrolizumab.
    Basnet S; Dhital R; Tharu B
    Medicina (Kaunas); 2019 May; 55(5):. PubMed ID: 31117208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radiation myelitis after pembrolizumab administration, with favorable clinical evolution and safe rechallenge: a case report and review of the literature.
    Carausu M; Beddok A; Langer A; Girard N; Bidard FC; Massiani MA; Ricard D; Cabel L
    J Immunother Cancer; 2019 Nov; 7(1):317. PubMed ID: 31753021
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic.
    Kang SP; Gergich K; Lubiniecki GM; de Alwis DP; Chen C; Tice MAB; Rubin EH
    Ann Oncol; 2017 Jun; 28(6):1388-1398. PubMed ID: 30052728
    [No Abstract]   [Full Text] [Related]  

  • 39. Late onset of subacute cutaneous lupus erythematosus following pembrolizumab therapy.
    Andersson NW; Zachariae C; Simonsen AB
    Eur J Cancer; 2021 Mar; 145():168-170. PubMed ID: 33486439
    [No Abstract]   [Full Text] [Related]  

  • 40. Pembrolizumab provides long-term survival benefits in advanced non-small cell lung cancer: The 5-year outcomes of the KEYNOTE-024 trial.
    Li F; Dong X
    Thorac Cancer; 2021 Dec; 12(23):3085-3087. PubMed ID: 34643064
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.